These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12720024)

  • 21. Nimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma.
    Costagliola C; Parmeggiani F; Caccavale A; Sebastiani A
    Am J Ophthalmol; 2006 Feb; 141(2):379-81. PubMed ID: 16458700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma.
    Martus P; Stroux A; Budde WM; Mardin CY; Korth M; Jonas JB
    Am J Ophthalmol; 2005 Jun; 139(6):999-1009. PubMed ID: 15953429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma.
    Collignon-Brach J
    Curr Eye Res; 1992 Jan; 11(1):1-3. PubMed ID: 1559386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension.
    Pachimkul P; Yuttitham K; Thoophom P
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S81-7. PubMed ID: 21717884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy of patients with primary open-angle glaucoma with proxofelin, a combined form of proxodolol].
    Ermakova VN; Malinina SL; Abdulkadyrova MZh; Filippova OM; Maliuta GD
    Vestn Oftalmol; 1999; 115(1):3-5. PubMed ID: 10207309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of oculo-pression-tonometry in the determination of outflow resistance].
    Ulrich C; Ulrich WD; Neunhöffer E; Fuhrmann P
    Fortschr Ophthalmol; 1987; 84(4):377-9. PubMed ID: 3666634
    [No Abstract]   [Full Text] [Related]  

  • 28. [Analysis of the effectiveness of beta-blockers for intraocular pressure and visual field in primary open-angle glaucoma].
    Dobre X
    Oftalmologia; 2008; 52(4):95-9. PubMed ID: 19354170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect.
    Kobayashi H; Kobayashi K
    J Glaucoma; 2011 Jan; 20(1):3-6. PubMed ID: 20520573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N; Sahin A; Gultekin S
    J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma.
    Martínez A; Sanchez-Salorio M
    Acta Ophthalmol; 2010 Aug; 88(5):541-52. PubMed ID: 19799592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical therapy of glaucoma.
    Singh A
    Ophthalmol Clin North Am; 2005 Sep; 18(3):397-408, vi. PubMed ID: 16054997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in visual function after intraocular pressure reduction using antiglaucoma medications.
    Prata TS; Piassi MV; Melo LA
    Eye (Lond); 2009 May; 23(5):1081-5. PubMed ID: 18670465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative evaluation of the tolerability of proxofelin and clofelin and their effects on the eye in patients with glaucoma].
    Ermakova VN; Malinina SL; Abdulkadyrova MZh
    Vestn Oftalmol; 2001; 117(1):6-8. PubMed ID: 11339049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-angle glaucoma: diagnosis and management.
    Jindra LF
    Hosp Pract (Off Ed); 1983 Oct; 18(10):114C, 114F, 114J passim. PubMed ID: 6413360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of initial topical medical therapy on short-term quality of life in newly diagnosed patients with primary glaucoma.
    Arora V; Bali SJ; Gupta SK; Vashisht P; Agarwal T; Sreenivas V; Dada T
    Indian J Ophthalmol; 2015 Jun; 63(6):511-5. PubMed ID: 26265642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Primary open-angle glaucoma].
    Bertaud S; Aragno V; Baudouin C; Labbé A
    Rev Med Interne; 2019 Jul; 40(7):445-452. PubMed ID: 30594326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular hypertension treatment study.
    Yablonski ME
    Arch Ophthalmol; 2004 Jul; 122(7):1088-9; author reply 1089. PubMed ID: 15249390
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.